BioPharma Resources

Drug Trial Radar · NCT05301322

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE IN ADULTS ≥65 YEARS OF AGE

Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,471 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,471

Actual

Start

Apr 13, 2022

Primary completion

Oct 12, 2022

Study completion Oct 12, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF). Additionally, the study will contribute data supporting the development of RSVpreF as a prophylactic vaccine against RSV disease in infants through maternal immunization and in older adults through active vaccination.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • RSVpreF VaccineBiological

    RSV Vaccine

  • PlaceboOther

    Placebo

  • Seasonal Inactivated Influenza VaccineBiological

    SIIV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or PlaceboTime frame: Within 7 days after Vaccination 1 or Vaccination 2
  2. Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination With RSVpreF or PlaceboTime frame: Within 7 days after Vaccination 1 or Vaccination 2
  3. Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 1Time frame: Within 1 month after Vaccination 1
  4. Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 2Time frame: Within 1 month after Vaccination 2
  5. Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1Time frame: Within 1 month after Vaccination 1
  6. Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 1 Month After Vaccination 2Time frame: Within 1 month after Vaccination 2
  7. Geometric Mean Ratio (GMR) of Neutralizing Titer (NTs) at 1 Month After Vaccination With RSVpreF for RSV Subfamily A and B in RSVpreF + SIIV Compared to RSVpreF AloneTime frame: 1 month after Vaccination 1 for Coadministration Group and 1 month after Vaccination 2 for Sequential-Administration Group
  8. GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers 1 Month After Vaccination With SIIV in the Coadministration Group to the Corresponding HAI Titers in the Sequential-Administration GroupTime frame: 1 month after Vaccination 1

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Paratus Clinical Research Canberra

    Bruce, Australian Capital Territory, Australia

  • Paratus Clinical Research Western Sydney

    Blacktown, New South Wales, Australia

  • Emeritus Research

    Botany, New South Wales, Australia

  • Genesis Research Services

    Broadmeadow, New South Wales, Australia

  • Northern Beaches Clinical Research

    Brookvale, New South Wales, Australia

  • Northside Health

    Coffs Harbour, New South Wales, Australia

  • Holdsworth House Medical Practice

    Darlinghurst, New South Wales, Australia

  • Paratus Clinical Research Central Coast

    Kanwal, New South Wales, Australia

  • The AIM Centre / Hunter Diabetes Centre

    Merewether, New South Wales, Australia

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

  • Australian Clinical Research Network

    Sydney, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Paratus Clinical Research Brisbane

    Albion, Queensland, Australia

  • Core Research Group

    Brisbane, Queensland, Australia

  • Griffith University

    Gold Coast Campus, Queensland, Australia

  • Nucleus Network Brisbane

    Herston, Queensland, Australia

  • Mackay Hospital and Health Service

    Mackay, Queensland, Australia

  • USC Clinical Trials Moreton Bay

    Morayfield, Queensland, Australia

  • USC Clinical Trials Centre

    Sippy Downs, Queensland, Australia

  • AusTrials - Taringa

    Taringa, Queensland, Australia

  • Core Research Group

    Taringa, Queensland, Australia

  • AusTrials Wellers Hill

    Tarragindi, Queensland, Australia

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

  • University of Tasmania

    Hobart, Tasmania, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Emeritus Research

    Camberwell, Victoria, Australia

  • Barwon Health

    Geelong, Victoria, Australia

  • Doctors of Ivanhoe

    Ivanhoe, Victoria, Australia

  • Nucleus Network Brisbane

    Melbourne, Victoria, Australia

  • Nucleus Network Melbourne

    Melbourne, Victoria, Australia

  • Institute for Respiratory Health

    Nedlands, Western Australia, Australia

  • Latitude Clinical Research

    Spearwood, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.